After Sputnik V, Russia approves another Covid-19 vaccine: Vladimir Putin

Published: 14 October, 2020 21:05 IST | IANS | Mumbai

The second Russian vaccine to get regulatory approval has been developed by the Vector State Research Centre of Virology and Biotechnology

Russian President Vladimir Putin
Russian President Vladimir Putin

Russian President Vladimir Putin on Wednesday announced that the country has registered the second Covid-19 vaccine, according to media reports.

Russia became the first country to give regulatory approval to a Covid-19 vaccine in August when Sputnik V was officially registered ahead of large-scale clinical trial, drawing criticism from some quarters in the scientific community.

The second Russian vaccine to get regulatory approval has been developed by the Vector State Research Centre of Virology and Biotechnology.

Vector's vaccine, dubbed "EpiVacCorona", relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant, according to details posted at ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world.

Putin said that a third Russian vaccine against Covid-19, developed by the Chumakov Centre, would also be registered in the near future, Sputnik news agency reported.

Russian Deputy Prime Minister Tatyana Golikova said that she tested EpiVacCorona vaccine herself and experienced no side effects, said the report.

"The Vector centre is also initiating post-registration clinical trials in the various regions of Russia that would include 40,000 volunteers," she was quoted as saying.

Keep scrolling to read more news

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Sign up for all the latest news, top galleries and trending videos from Mid-day.com

Subscribe
loading image
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK